Eighteen-month clinical safety and efficacy outcomes of sirolimus-, paclitaxel- and zotarolimus-drug eluting stents in diabetic patients undergoing percutaneous coronary intervention for complex coronary artery stenosis.
- Author:
Eric CHONG
1
;
Kian Keong POH
;
Shen LIANG
;
Xu Min HOU
;
Huay Cheem TAN
Author Information
- Publication Type:Clinical Trial
- MeSH: Aged; Angioplasty, Balloon, Coronary; Coronary Restenosis; prevention & control; Coronary Stenosis; complications; surgery; Diabetes Complications; Drug-Eluting Stents; Female; Humans; Immunosuppressive Agents; administration & dosage; Male; Middle Aged; Myocardial Infarction; Paclitaxel; administration & dosage; Sirolimus; administration & dosage; analogs & derivatives; Survival Analysis; Treatment Outcome
- From:Annals of the Academy of Medicine, Singapore 2010;39(5):381-384
- CountrySingapore
- Language:English
-
Abstract:
INTRODUCTIONThis was a single centre registry study on clinical efficacy and safety of drug-eluting stent (DES) in diabetic patients undergoing percutaneous coronary intervention (PCI) for complex coronary lesions.
MATERIALS AND METHODSA total of 288 diabetic patients who underwent elective PCI between September 2003 and June 2006 in our centre were enrolled and followed-up for 18 months. Among them, 79 (27.4%) patients received sirolimus-eluting stent (SES), 138 (47.9%) paclitaxel-eluting stent (PES) and 71 (24.7%) zotarolimus-eluting stent (ZES). The endpoints were major adverse cardiac events (MACE) and stent thrombosis rates.
RESULTSBaseline demographics were comparable among the 3 DES groups (median age was 60 years; 69% men). Complex lesions (defined as ACC/AHA type C stenosis) accounted for 55.6% of the total lesions: SES (50.6%), PES (65.2%) and ZES (43.7%), P = 0.005. At 18 months follow-up, the composite endpoint of MACE was found in 12.7% in SES group, 8.7% in the PES group, 12.7% in ZES group and (P = 0.55). Stent thrombosis (ST) occurred in 1 patient (1.3%) in the SES group, 2 patients (1.4%) in PES group and 1 patient (1.4%) in ZES group, respectively (P = 1.00).
CONCLUSIONThe use of DES for elective PCI in diabetic patients was associated with favourable intermediate-term clinical outcomes with no significant differences in efficacy among the 3 groups. Stent thrombosis had low event occurrence rate.
